Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 7/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4828522 | 0.91 | CHEK1 (0.40) | TLR7SCN9A | |
| SCHEMBL4760698 | 0.86 | ACKR3 (0.48) | ENPP2 | |
| SCHEMBL4724392 | 0.85 | ALDH1A1 (0.46) | ENPP2GAAALDH1A1 | |
| SCHEMBL6004876 | 0.84 | TLR7 (0.44) | HPGDSTLR7GAALMNASCN9A | |
| SCHEMBL4762022 | 0.84 | TLR7 (0.43) | HPGDSTLR7GAALMNASCN9A | |
| SCHEMBL4761789 | 0.83 | TGFBR1 (0.44) | ENPP2PIN1HPGDSTLR7TSHR | |
| SCHEMBL6004597 | 0.82 | TLR7 (0.42) | HPGDSTLR7LMNASCN9A | |
| SCHEMBL6003997 | 0.78 | HDAC3 (0.40) | HPGDSTLR7GAA | |
| SCHEMBL6002763 | 0.76 | PIN1 (0.40) | ENPP2PIN1TLR7ALDH1A1 | |
| SCHEMBL4826461 | 0.74 | CHEK1 (0.37) | TLR7SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | ENPP2 266/4885PIN1 598/4885HPGDS 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.